866-997-4948(US-Canada Toll Free)

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 52 Pages

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H2 2016, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 1 respectively.Vaginal Atrophy (Atrophic Vaginitis).

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginal Atrophy (Atrophic Vaginitis) Overview 6
Therapeutics Development 7
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 8
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 12
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 13
Allergan Plc 13
EndoCeutics, Inc. 14
Foamix Pharmaceuticals Ltd. 15
Ligand Pharmaceuticals, Inc. 16
Mithra Pharmaceuticals S.A. 17
PEPTONIC medical AB 18
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Estetrol - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
estradiol hemihydrate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
lasofoxifene tartrate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
oxytocin - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
prasterone - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
WC-3011 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 41
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 42
Featured News & Press Releases 42
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor 42
Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study 42
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting 43
Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 44
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 45
Jul 17, 2015: Last subject exits Peptonic Medicals phase 2b VVA study 46
Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment 46
Mar 23, 2015: Peptonic Medicals formulation patent to be approved in the USA 47
Mar 18, 2015: Patient recruitment to Peptonic Medicals phase 2b study soon completed 47
Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin 48
Dec 01, 2014: Peptonic Medicals formulation patent to be approved in Europe 48
Oct 28, 2014: First patients included in Peptonic Medical ABs clinical phase 2b study 48
Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study 49
Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study 49
Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H2 2016 13
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H2 2016 14
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 15
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 16
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals S.A., H2 2016 17
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H2 2016 41

List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Top 10 Molecule Types, H2 2016 26
Number of Products by Stage and Top 10 Molecule Types, H2 2016 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *